Canakinumab

Generic Name
Canakinumab
Brand Names
Ilaris
Drug Type
Biotech
Chemical Formula
-
CAS Number
914613-48-2
Unique Ingredient Identifier
37CQ2C7X93
Background

Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain ...

Indication

Canakinumab is indicated for the treatment of periodic fever syndromes in specific patient populations. In patients ≥4 years of age, canakinumab is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). In adult and pediatric patients, canakinum...

Associated Conditions
Adult Onset Still's Disease, Cryopyrin-associated Periodic Syndromes (CAPS), Familial Cold Autoinflammatory Syndrome (FCAS), Familial Mediterranean Fever (FMF ), Gout Flares, Mevalonate Kinase Deficiency, Muckle-Wells Syndrome (MWS), Systemic Juvenile Idiopathic Arthritis (SJIA), Tumour necrosis factor receptor-associated periodic syndrome
Associated Therapies
-
Clinical Trials
Related News

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

First Posted Date
2023-08-09
Last Posted Date
2024-06-26
Lead Sponsor
NYU Langone Health
Target Recruit Count
10
Registration Number
NCT05984602
Locations
🇺🇸

NYU Langone Ambulatory Care Center East 38th Street, New York, New York, United States

🇺🇸

Ambulatory Care Center, New York, New York, United States

🇺🇸

Clinical Cancer Center, New York, New York, United States

A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer

Phase 3
Terminated
Conditions
Lung Cancer
Interventions
Drug: Placebo
Drug: Canakinumab
First Posted Date
2023-02-13
Last Posted Date
2023-02-13
Lead Sponsor
Mario Negri Institute for Pharmacological Research
Target Recruit Count
350
Registration Number
NCT05725343
Locations
🇮🇹

Ente Ospedaliero Ospedali Galliera, Genova, Italy

🇮🇹

Ospedale San Martino, Genova, Italy

🇮🇹

IRST Meldola, Meldola, Italy

and more 3 locations

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

First Posted Date
2022-12-08
Last Posted Date
2024-12-20
Lead Sponsor
Uma Borate
Target Recruit Count
110
Registration Number
NCT05641831
Locations
🇺🇸

UT Southwestern Medical Center at Dallas, Dallas, Texas, United States

🇺🇸

Weill Cornell Medical College, New York, New York, United States

🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 1 locations

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

First Posted Date
2022-09-10
Last Posted Date
2024-05-23
Lead Sponsor
John Harris
Target Recruit Count
45
Registration Number
NCT05535738
Locations
🇺🇸

University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States

Study of Canakinumab in Patients With Myelofibrosis

First Posted Date
2022-07-21
Last Posted Date
2024-11-28
Lead Sponsor
John Mascarenhas
Target Recruit Count
10
Registration Number
NCT05467800
Locations
🇺🇸

Mayo Clinic Arizona, Phoenix, Arizona, United States

🇺🇸

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

and more 4 locations

Canakinumab for the Treatment of Postprandial Hypoglycemia

First Posted Date
2022-06-02
Last Posted Date
2024-07-03
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
56
Registration Number
NCT05401578
Locations
🇨🇭

University Hospital Basel, Division of Endocrinology, Diabetes and Metabolism, Basel, Switzerland

🇨🇭

Cantonal Hospital Olten, Division of Endocrinology, Olten, Switzerland

A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer

First Posted Date
2021-05-27
Last Posted Date
2024-06-18
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
41
Registration Number
NCT04905316
Locations
🇺🇸

Memorial Sloan Kettering Commack, Commack, New York, United States

🇺🇸

Memorial Sloan Kettering Nassau, Uniondale, New York, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

First Posted Date
2021-03-23
Last Posted Date
2024-05-17
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
33
Registration Number
NCT04810611
Locations
🇺🇸

The Ohio State University Wexner Medical Center ., Columbus, Ohio, United States

🇺🇸

Massachusetts General Hospital ., Boston, Massachusetts, United States

🇺🇸

City Of Hope National Med Center Oncology, Duarte, California, United States

and more 3 locations

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

First Posted Date
2021-03-09
Last Posted Date
2024-11-27
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
50
Registration Number
NCT04789681
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD

Phase 3
Active, not recruiting
Conditions
Adult Onset Still's Disease
Interventions
Biological: Canakinumab
First Posted Date
2021-01-22
Last Posted Date
2024-08-07
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
14
Registration Number
NCT04717635
Locations
🇯🇵

Novartis Investigative Site, Chiba, Japan

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy